Similar drugsTo uncover
Dosage form: & nbspsublingual tablets
Composition:

For one tablet:

active substance: extract of the allergen from the mixture of pollen of grasses (hedgehogs, spikelets common, long-haired, meadow grass, timothy grass) in equal proportions 100 IR * and 300 IR;

Excipients: microcrystalline cellulose 12.5 mg, croscarmellose sodium 2.5 mg, silicon dioxide colloid 0.5 mg, magnesium stearate 0.7 mg, lactose monohydrate up to 100 mg.

* IR - The Reactivity Index is the biological standardization unit.

Description:

Round, biconvex tablets from white to beige with possible interspersions from light brown to dark brown, with engraving 100 on each side for a tablet with activity 100 IR and engraving 300 on each side for a tablet with activity 300 IR.

Pharmacotherapeutic group:MIBP is an allergen
ATX: & nbsp
  • Allergens of grass pollen
  • Indications:

    Allergen-specific immunotherapy (ASIT) is indicated for patients with type 1 allergic reaction (IgE mediated), manifested in the form of rhinitis or rhinoconjunctivitis (medium-heavy or severe course), which has increased sensitivity to the pollen of meadow grasses (hedgehogs, spikelets, long-legged meadow grass, meadow grass, timothy grass), confirmed by positive results in skin testing and / or increased content of a specific IgE.

    Immunotherapy can be given to adults and children from the age of 5.

    Contraindications:

    - Hypersensitivity to any of the excipients included in the formulation;

    - uncontrolled and / or severe bronchial asthma (volume of forced expiration less than 70%);

    - severe immunodeficiencies or autoimmune diseases;

    - malignant neoplasms;

    - inflammatory diseases of the oral mucosa (erosive-ulcerative form of red flat lichen, ulceration of the oral mucosa, mycosis of the oral mucosa);

    - hereditary intolerance of galactose, lactase deficiency of Lapp, impaired absorption of glucose and galactose;

    - therapy with beta-blockers.

    Pregnancy and lactation:

    Pregnancy

    Data on the use of the drug ORALEYR ® during pregnancy are absent. The results of animal studies did not reveal direct or indirect adverse effects on reproductive function.

    Do not start immunotherapy during pregnancy. If the pregnancy occurred during treatment, the therapy can be continued only under the close supervision of the doctor.

    Breast-feeding

    Data on the isolation of the active substance with breast milk are not available. Nevertheless, it is not recommended to begin the course of ASIT during the period of breastfeeding. Since the systemic effect of the active substance ORRALEY® on the lactating woman is negligible, the use of ORALEIR® during breastfeeding is possible after an assessment of the risk-benefit ratio.

    Dosing and Administration:

    Treatment with ORALEYR® should be prescribed and started by a doctor who has appropriate training and experience in the treatment of allergic diseases. If the drug is used in pediatric practice, the physician should have appropriate experience in the treatment of children.

    It is recommended to take the first ORALEYR ® tablet under the supervision of a doctor to monitor the patient for 30 minutes.

    Doses and treatment regimen

    Treatment consists of two stages: initial therapy (starting from three days of dose escalation) and maintenance therapy.

    Initial therapy corresponds to the first month of treatment with ORALIIR® 100 IR and 300 IR.

    Scheme of ORALEYR® preparation at the initial stage:

    Small blister:

    1 day - 1 tablet 100 IR

    Day 2 - 2 tablets 100 IR

    From 3 to 30 day, take 1 tablet of the drug with activity 300 IR:

    Large blister:

    3 day - 1 tablet 300 IR

    4 day - 1 tablet 300 IR

    5 day - 1 tablet 300 IR

    -

    Day 30 - 1 tablet 300 IR

    From the second month they pass to the stage of maintenance therapy and take 1 tablet of the drug with an activity of 300 IR per day until the end of the dusting season.

    Duration of treatment

    Allergenspecific immunotherapy is recommended to be carried out by the above two-stage courses (starting 4 months before the expected flowering season and continuing until the end of the flowering season) for 3-5 years.

    A long-term study showed that after the ASTI has been carried out for the recommended schedule for 3 consecutive years, the effect persists in the following season if there is no treatment.

    If the improvement did not occur during the first season of flowering, it is not advisable to continue treatment.

    If the admission admission is less than 7 days, you can continue treatment without changes. If you miss more than 7 days, it is recommended to continue treatment under the supervision of a doctor.

    Application in childhood

    The safety and efficacy of treatment in children younger than 5 years are not established.

    The recommended doses of the drug for children older than 5 years and teenagers are the same as for adults.

    Mode of application

    The tablet should be placed under the tongue and kept until completely dissolved (for at least 1 minute), then swallowed.

    The drug is recommended to be taken on an empty stomach during the day.

    Side effects:

    Possible adverse reactions are grouped according to systems and organs and frequency of occurrence: very often (≥1 / 10), often (≥1 / 100 to <1/10), infrequently (≥1 / 1000 to <1/100), rarely ( ≥1 / 10000 to <1/1000).

    Within each group, serious reactions are listed first.

    Like any drug, ORALAYR® can cause side reactions in some patients.

    During treatment, both local and general adverse reactions may occur.

    Reactions at the site of application (eg, itching in the mouth and irritation in the throat) usually occur at the beginning of therapy, are temporary and decrease over time. If the patient develops reactions at the site of application, then symptomatic therapy (for example, antihistamines) is possible.

    Immediately stop taking the drug and consult a doctor if the following symptoms occur: severe symptoms in the throat region or systemic allergic reactions (i.e., rapid development of reactions on the skin and / or mucous membranes, shortness of breath, persistent abdominal pain, falling blood pressure and / or associated symptoms).

    Treatment can be resumed only after a doctor's consultation.

    Infectious diseases: often - nasopharyngitis, rhinitis; infrequently - oral herpes, otitis.

    On the part of the blood and lymphatic system: infrequent - enlarged lymph nodes.

    From the immune system: infrequently - hypersensitivity, oral allergic syndrome.

    Disorders of the psyche: infrequently - depression.

    From the nervous system: very often - headache; infrequently - a change in taste sensations, drowsiness, dizziness; rarely - anxiety.

    From the side of the organ of vision: often - itching in the eyes, conjunctivitis, lacrimation; infrequent - redness of the eyes, swelling of the eyes, dry eye syndrome.

    From the side of the hearing organ and labyrinthine disorders: often - itching of the ears; infrequently - discomfort in the ear.

    From the side of the vessels: rarely - redness.

    From the respiratory system, chest and mediastinum: very often irritation in the throat; often asthma, allergic rhinitis (nasal congestion, sneezing, runny nose, nose discomfort), cough, pain in the oropharynx, pharyngeal edema, sinus congestion, dyspnoea, dysphonia, dry throat, blisters in the oropharynx, discomfort in the oropharynx; infrequent - numbness in the throat, a feeling of tightness in the throat, wheezing, swelling of the larynx.

    Disorders from the gastrointestinal tract: very often - itching in the mouth; often - abdominal pain, diarrhea, vomiting, edema of the mouth, tongue itching, swelling of the lips, oral paresthesia, dyspepsia, tongue edema, oral hypoesthesia, stomatitis, itching of lips, discomfort in the mouth, nausea, burning mouth syndrome, dry mucous oral cavity shell, swallowing disorder; infrequently - pain in the oral cavity. Gingivitis, cheilitis, gastritis, glossitis, salivary gland enlargement, gastroesophageal reflux, disorders in the area of ​​the tongue (clinical signs of an allergic reaction in the area of ​​the tongue associated with local release of histamine), increased salivation, ulcerative stomatitis, pain in the esophagus, swelling of the soft palate, disorders in the mouth (clinical signs of an allergic reaction in the mouth,associated with the local release of histamine), pain when swallowing, belching.

    From the skin and subcutaneous tissues: often - hives, itching, atopic dermatitis; infrequently - Quincke's edema, rash, acne; rarely - swelling of the face.

    General disorders and disorders at the site of administration: often - discomfort in the chest; infrequently - a feeling of restraint in the throat, asthenia, flu-like syndrome.

    Laboratory and instrumental data: rarely - an increase in the number of eosinophils.

    Trauma, intoxication and complications of manipulation: rarely - a tendency to mechanical damage to the skin.

    In clinical trials with adult patients, a reduction in the number of side effects in treatment in the second and third flowering season was found compared with the first season.

    Side effects when used in children and adolescents

    The following side effects occur in children and adolescents more often than in adults: very often - cough, nasopharyngitis, edema of the oral cavity; often - oral allergic syndrome, cheilitis, glossitis, a feeling of tightness in the throat, discomfort in the ear.

    In addition, children and adolescents had the following adverse reactions: often tonsillitis, bronchitis; infrequently - a pain in the chest.

    Additional side effects found during use in children, adolescents and adults (post-registration experience, frequency of occurrence unknown): exacerbation of asthma, systemic allergic reaction, eosinophilic esophagitis.

    Overdose:

    No cases of overdose with ORRALE® were reported.

    If the prescribed dosage of ORALEYR® is exceeded, the risk of adverse reactions increases, including severe local and systemic reactions. In case of serious symptoms such as Quincke's edema, difficulty swallowing, shortness of breath, voice change, a feeling of restraint in the neck, you should immediately consult a doctor.

    The adverse reactions that occur when the prescribed dose is exceeded require symptomatic treatment.

    Interaction:

    The results of clinical studies showed the lack of drug interaction with drugs for symptomatic treatment of allergies (antihistamines, steroids).

    Data on the possible risk of simultaneous treatment with ORALEYR® and immunotherapy with other allergens are not available.

    Caution should be exercised in prescribing and carrying out specific immunotherapy for patients taking tricyclic antidepressants and monoamine oxidase inhibitors, since the use of epinephrine to stop possible allergic reactions in such patients can lead to life-threatening side effects.

    Clinical experience of simultaneous vaccination and treatment with ORALEYR® absent. Vaccination can be carried out without interruption of treatment only after consulting a doctor.

    Special instructions:

    When surgical operations in the oral cavity, including the removal of teeth, it is necessary to interrupt therapy until complete cure (at least for 7 days).

    In the case of severe allergic reactions, the doctor may recommend the use of epinephrine. It should be noted that in patients taking tricyclic antidepressants, monoamine oxidase inhibitors, the risk of side effects on the introduction of epinephrine up to a lethal outcome increases.

    It was reported about the occurrence of eosinophilic esophagitis associated with sublingual immunotherapy. If in the treatment with ORRALER® there are severe or persistent symptoms from the upper part of the digestive system,including a violation of swallowing or chest pain, therapy with ORALEYR® should be interrupted and consulted by a doctor. Treatment can be resumed only after a doctor's consultation.

    Effect on the ability to drive transp. cf. and fur:

    The drug does not affect the ability to drive vehicles and mechanisms.

    Form release / dosage:

    Tablets are sublingual, 100 IR and 300 IR.

    Packaging:

    For 3 tablets (100 IR) in the Alu / Alu blister. For 28 tablets (300 IR) in the Alu / Alu blister. One blister of each dosage in a pack of cardboard with instructions for use.

    For 30 tablets (300 IR) in the Alu / Alu blister. 1 or 3 blisters in a pack of cardboard with instructions for use.

    Storage conditions:

    Transportation conditions. Transport at a temperature not exceeding 25 ° C.

    Storage conditions. Store at a temperature not exceeding 25 ° C. Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-001119
    Date of registration:03.11.2011 / 04.12.2013
    Expiration Date:03.11.2016
    The owner of the registration certificate:Stallergen, AOStallergen, AO France
    Manufacturer: & nbsp
    CENEXI France
    Representation: & nbspStallergen Vostok, OOOStallergen Vostok, OOO
    Information update date: & nbsp10.06.2017
    Illustrated instructions
      Instructions
      Up